Despite the advent of new effective therapies for multiple myeloma (MM), treatment of patients with relapsed/ refractory myeloma (RRMM) remains challenging. Median survival is particularly poor if patients develop resistance to ImiDs or proteasome inhibitors, with a clinical course often characterized by poor responses, early relapses, and a rapid march through numerous lines of therapy [1] . Allogeneic hematopoietic-cell transplant (alloHCT) is the only curative treatment for MM, and although historically high rates of non-relapse mortality (NRM) are improving, relapse remains an important challenge. Using CD34
+ selected (ex vivo T-cell depleted) allografts in RRMM patients, our institution has reported 1-year NRM of 18% and low rates of acute and chronic graft versus host disease (2% and 0%, respectively), but with modest 2-year progression-free survival (PFS) of 31% and a median PFS duration of 13.5 months [2] . This highlights a need for improved strategies in this challenging population. Checkpoint inhibitors have demonstrated efficacy in solid and hematologic malignancies [1] . While studies of these agents were recently put on hold by the FDA due to unexpected toxicity, preliminary data has shown response rates of 50-60% and median response durations exceeding 14 months with the combination of pembrolizumab, dexamethasone, and lenalidomide, or pomalidomide [3, 4] . With increasingly widespread experience with checkpoint inhibitors, their association with immune-mediated adverse events has also become well established and has contributed to our understanding of their biological behavior [5] . Here we describe a case in which pembrolizumab used for relapse prevention after alloHCT in a patient with MM was associated with immune-mediated neutropenia. This case is unique for the severity and refractoriness of the neutropenia observed, for the alloreactive host-versus-graft etiology of the toxicity, and in that it was observed in a recipient of an ex vivo T-cell depleted allograft.
The patient is a 49-year-old woman with no previous medical history who was diagnosed with Revised MM International Staging System (R-ISS) stage II kappa light chain MM with 24% marrow plasma cells, a solitary lytic humeral lesion, and high-risk cytogenetic features including p53 deletion, add 1q, and deletion 13q. In the 3 years prior to alloHCT, she received multiple lines of therapy including: bortezomib/lenalidomide/dexamethasone, carfilzomib/lenalidomide/dexamethasone (KRD), dexamethasone/thalidomide/ cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE), melphalan 200 mg/m 2 autologous HCT, consolidative KRD, re-treatment KRD, and pomalidomide/daratumumab/dexamethasone.
After achieving a very good partial response with salvage daratumumab/pomalidomide/dexamethasone, she proceeded to CD34 + selected 10/10 matched-unrelated-donor peripheral-blood alloHCT conditioned with busulfan, melphalan, and fludarabine, as we have previously described [2] . AlloHCT was well-tolerated and resulted in day+30 and +100 complete response (CR), with day+100 cytogenetic minimal residual disease (MRD) below the 5% FISH sensitivity threshold (<1% add 1q; <1% p53 deletion; 0% deletion 13q). Flow cytometry was not reported at these time points. Given her high-risk disease and encouraging preliminary data reported with pembrolizumab/lenalidomide/dexamethasone in MM [3] , we initially administered single agent pembrolizumab 2 mg/kg at 6-week intervals while monitoring for toxicities. If safe and well-tolerated, we planned to increase administration frequency to biweekly and add lenalidomide and dexamethasone, modeled after the experience by San Miguel et al. [3] At day+118, with full three-line engraftment, without signs of graft-versushost disease (GVHD), and with disease in CR and low level cytogenetic MRD (assessed at day+100), she received the first pembrolizumab dose. The following week she developed a biopsy-proven eosinophilic folliculitis that resolved with topical steroids.
A second dose of pembrolizumab was administered 6 weeks after the first (day+160). One week later, the patient presented with fever, upper respiratory symptoms and new absolute neutropenia (Fig. 1) . Broad-spectrum antibiotics were administered. No infectious etiology was identified including parvovirus, Ebstein-Barr virus (EBV), cytomegalovirus (CMV), HIV, viral hepatitis, HHV-6, aspergillus, and tuberculosis. She had no nutritional deficiencies of folate, vitamin B12, or iron. Autoimmune and vasculitic markers including ANA, anti-neutrophil antibodies, anti-RO, anti-La, cANCA, and pANCA were all within normal limits. Non-specific inflammatory markers were however above the upper limit of normal (ESR 57 mm The patient meanwhile did not respond to standard approaches to treat her absolute neutropenia, including filgrastim, pegfilgrastim, and sargramostim, high-dose intravenous immune globulin (1 g/kg IV q24h; 2 doses), highdose steroids (methylprednisolone IV and oral prednisone (PO), 1-2 mg/kg per day), rituximab (375 mg/m 2 IV; 4 doses), and cyclosporine (1-2 mg/kg IV, 3 mg/kg PO) (Fig. 1) . When elevated concentrations of plasma interleukin 6 were identified, tocilizumab (4 mg/kg IV once) was also trialed without response. The patient remained absolutely neutropenic for a total of 64 days during which time she sustained numerous infections including sinusitis, blepharitis, and periorbital cellulitis, herpes simplex virus oral ulceration, and suspected Helicobacter pylori gastritis. She later developed a rapidly progressive necrotizing pseudomonal facial cellulitis that damaged nasal cartilage, and that emphasized the urgency of re-establishing effective host immunity.
Given the patient's allograft had been depleted of donor T cells, we suspected that the reactive LGLs associated with this neutropenia were of host origin and were mounting host-vs-graft alloreactivity. Indeed, while peripheral-blood B-cell and myeloid compartments were consistently 100% donor origin, T-cell populations were predominantly host (77-93%) at all time points measured. The CD8 + T-cell
LGL population was also ultimately confirmed to be 93% host origin by flow sorting and short-tandem repeat PCR, 228 days after alloHCT and 110 and 78 days after each pembrolizumab dose. Given the persistent neutropenia and severe complicating infections, we decided to perform a third transplant using her stored autologous cells to re-establish effective hemato and granulopoiesis. She was conditioned with fludarabine (25 mg/m 2 days −2 and −1) and melphalan (140 mg/m 2 day −1), and on post alloHCT day 231, she was reinfused with 7.34 × 10 6 previously banked autologous CD34 + cells.
Neutrophil engraftment was achieved on day 9 and has been maintained since (Fig. 1) . Multiple myeloma was maintained in deep CR with low levels of MRD (0.00018% by 10-color flow) until confirmed relapse with 60% marrow plasma cells at 385 days after alloHCT, 268 days after the first pembrolizumab dose, and 155 days after autoHCT. At the time of writing, she is being considered for local clinical trials. This case adds to accumulating reports describing the ability of checkpoint inhibitors to induce immune-mediated toxicities [5] . It also underlines the extent of this potential in that potent alloreactivity occurred in the context of an immune system in early recovery after T-cell depleted alloHCT. While this patient's T-cell counts and subsets before and after pembrolizumab were within ranges observed in other CD34
+ selected alloHCT recipients at our institution [6, 7] , the marked and isolated increase in activated CD8 subsets and their predominantly host chimerism supports their implication in host-mediated alloimmune destruction of donor neutrophils and neutrophil precursors. The patient also had transient HHV-6 (day 20-30) and CMV (day 32-63) viremias post alloHCT, the latter resolving with ganciclovir. The contribution of these to the LGL resurgence and neutropenia are unknown but less strongly supported given their resolution predated the neutropenia onset by >100 days. It is possible but unknown whether the use of pembrolizumab in a setting with few targetable tumor cells increased the potential for off-target activity. We note however that this patient's high-risk disease also achieved the longest response since first relapse (1 year after alloHCT, 9 months after pembrolizumab autoHCT) and deepest CR since its diagnosis (cytogenetic MRD-negative; flow cytometry MRD-positive CR with 0.00018% plasma cells). These observations could be attributable to on-target antitumor activity, however the relative contributions of alloHCT, pembrolizumab, and second autoHCT to these observations are unknown.
The association of checkpoint inhibitors with adverse immunologic events and well-defined systemic autoimmune disease has been widely reported in solid and hematologic malignancies, and recently reviewed in the context of alloHCT [8] [9] [10] . We are aware of two and five cases of ipilimumab and nivolumab-associated autoimmune neutropenia, respectively [11] [12] [13] [14] [15] [16] . This report is the first case of immune neutropenia associated with pembrolizumab of which we are aware, and the first describing an alloimmune phenomenon in the context of T-cell-depleted alloHCT. In all other reported cases, neutropenia resolved with drug cessation and/or administration of immune suppression via glucocorticoids or immune globulin. The uniquely refractory nature of our case may be reflective of unique Severe pembrolizumab-associated neutropenia after CD34 + selected allogeneic hematopoi…characteristics of immune reconstitution after alloHCT, the chimeric immunohematopoietic environment observed after T-cell-depleted allografts, or the use of pembrolizumab in the absence of active disease. Wide-ranging reports describe checkpoint inhibitor association with potent off-target immune responses. This case adds to this growing literature and highlights the importance of careful and closely monitored use of these new drugs. Put together, these cases advocate for continued immunobiologic and clinical study of these novel agents to improve our capacity to harness their promising antitumor potential without potentiating adverse immune-related events.
